Dr. Todd H. Lanman served as a principal investigator in the U.S. clinical trial supporting the FDA approval of the Synergy Disc®, a next-generation artificial cervical disc designed for single-level use. The device demonstrated strong clinical outcomes compared to fusion and is engineered to both preserve motion and improve spinal alignment.
Dr. Lanman will present findings from the study at ISASS 2026, contributing to the growing body of evidence supporting cervical disc arthroplasty as a viable option for a broader range of patients.
